Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (e)-beta-caryophyllene
2. Beta-caryophyllene
3. Caryophyllene, (r*,4z,9s*)-(+-)-isomer
4. Caryophyllene, (r-(r*,4e,9s))-isomer
5. Caryophyllene, (r-(r*,4z,9s*))-isomer
6. Caryophyllene, (s-(r*,4e,9s*))-isomer
7. Caryophyllene, (s-(r*,4z,9s*))-isomer
8. Isocaryophyllene
9. Trans-caryophyllene
1. Beta-caryophyllene
2. Trans-caryophyllene
3. (-)-trans-caryophyllene
4. 87-44-5
5. L-caryophyllene
6. (-)-beta-caryophyllene
7. (-)-(e)-caryophyllene
8. .beta.-caryophyllene
9. B-caryophyllene
10. Trans-beta-caryophyllene
11. (e)-caryophyllene
12. (e)-beta-caryophyllene
13. Beta-caryophylene
14. Trans-.beta.-caryophyllene
15. (-)-caryophyllene
16. .beta.-caryophyllen
17. Fema No. 2252
18. Chebi:10357
19. (e)-beta-caryophylene
20. .beta.-(e)-caryophyllene
21. Beta-caryophyllen
22. Nsc-11906
23. (1r,4e,9s)-4,11,11-trimethyl-8-methylidenebicyclo[7.2.0]undec-4-ene
24. G-caryophyllene
25. 8-methylene-4,11,11-(trimethyl)bicyclo(7.2.0)undec-4-ene
26. Nsc 11906
27. (1r,4e,9s)-4,11,11-trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene
28. Bicyclo(7.2.0)undec-4-ene, 8-methylene-4,11,11-trimethyl-, (e)-(1r,9s)-(-)-
29. E-.beta.-caryophyllene
30. Bhw853au9h
31. .beta.-caryophyllene, (-)
32. Tincturoid
33. 8-methylene-4,11,11-(trimethyl)bicyclo[7.2.0]undec-4-ene
34. Nsc11906
35. Caryophyllene B
36. Beta-cariofillene
37. (1r,4e,9s)-4,11,11-trimethyl-8-methylene-bicyclo[7.2.0]undec-4-ene
38. Beta-caryophillene
39. (1r,4e,9s)-4,11,11-trimethyl-8-methylenebicyclo(7.2.0)undec-4-ene
40. Bicyclo[7.2.0]undec-4-ene, 8-methylene-4,11,11-trimethyl-, (e)-(1r,9s)-(-)-
41. Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, [1r-(1r*,4e,9s*)]-
42. E-beta-caryophyllene
43. Mfcd00075925
44. Caryophyllene, (e)
45. (?)-b-caryophyllene
46. Beta-(e)-caryophyllene
47. Beta-trans-caryophyllene
48. (?)-trans-caryophyllene
49. Dsstox_cid_4739
50. Caryophyllene [mi]
51. .beta.-trans-caryophyllene
52. (-)-i(2)-caryophyllene
53. Dsstox_rid_77517
54. Dsstox_gsid_24739
55. Chembl445740
56. Beta-caryophyllene [fcc]
57. Dtxsid8024739
58. Beta-caryophyllene [inci]
59. Bicyclo(7.2.0)undec-4-ene, 4,11,11-trimethyl-8-methylene-, (1r,4e,9s)-
60. Hy-n1415
61. Zinc8234282
62. .beta.-caryophyllene [fhfi]
63. Tox21_301497
64. (1s,9r)-6,10,10-trimethyl-2-methylenebicyclo[7.2.0]undec-5-ene
65. Bdbm50529607
66. S6058
67. Akos024283988
68. Lmpr0103120001
69. Beta-caryophyllene, >=80%, Fcc, Fg
70. Cas-87-44-5
71. Ncgc00142620-01
72. Ncgc00255159-01
73. (-)-trans-caryophyllene, Analytical Standard
74. Cs-0016839
75. C09629
76. Beta-caryophyllene 2000 Microg/ml In Acetonitrile
77. Q421614
78. W-109317
79. (-)-trans-caryophyllene, >=98.5% (sum Of Enantiomers, Gc)
80. Trans-(1r,9s)-4,11,11-trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene
81. 8-methylene-4,11,11-(trimethyl)bicyclo(7.2.0)undec-4-ene, (1r,4e,9s)-
82. Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, (e)-(1r,9s)-(-)-
83. Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, [1r- (1r*,4e,9s*)]-
| Molecular Weight | 204.35 g/mol |
|---|---|
| Molecular Formula | C15H24 |
| XLogP3 | 4.4 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 0 |
| Rotatable Bond Count | 0 |
| Exact Mass | 204.187800766 g/mol |
| Monoisotopic Mass | 204.187800766 g/mol |
| Topological Polar Surface Area | 0 Ų |
| Heavy Atom Count | 15 |
| Formal Charge | 0 |
| Complexity | 293 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Anti-Inflammatory Agents, Non-Steroidal
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. (See all compounds classified as Anti-Inflammatory Agents, Non-Steroidal.)
Digital Content 
NEWS #PharmaBuzz
Market Place
ABOUT THIS PAGE
39
PharmaCompass offers a list of Beta-Caryophyllene API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Beta-Caryophyllene manufacturer or Beta-Caryophyllene supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Beta-Caryophyllene manufacturer or Beta-Caryophyllene supplier.
PharmaCompass also assists you with knowing the Beta-Caryophyllene API Price utilized in the formulation of products. Beta-Caryophyllene API Price is not always fixed or binding as the Beta-Caryophyllene Price is obtained through a variety of data sources. The Beta-Caryophyllene Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A beta-Caryophyllene, >=80%, FCC, FG manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of beta-Caryophyllene, >=80%, FCC, FG, including repackagers and relabelers. The FDA regulates beta-Caryophyllene, >=80%, FCC, FG manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. beta-Caryophyllene, >=80%, FCC, FG API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A beta-Caryophyllene, >=80%, FCC, FG supplier is an individual or a company that provides beta-Caryophyllene, >=80%, FCC, FG active pharmaceutical ingredient (API) or beta-Caryophyllene, >=80%, FCC, FG finished formulations upon request. The beta-Caryophyllene, >=80%, FCC, FG suppliers may include beta-Caryophyllene, >=80%, FCC, FG API manufacturers, exporters, distributors and traders.
beta-Caryophyllene, >=80%, FCC, FG Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of beta-Caryophyllene, >=80%, FCC, FG GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right beta-Caryophyllene, >=80%, FCC, FG GMP manufacturer or beta-Caryophyllene, >=80%, FCC, FG GMP API supplier for your needs.
A beta-Caryophyllene, >=80%, FCC, FG CoA (Certificate of Analysis) is a formal document that attests to beta-Caryophyllene, >=80%, FCC, FG's compliance with beta-Caryophyllene, >=80%, FCC, FG specifications and serves as a tool for batch-level quality control.
beta-Caryophyllene, >=80%, FCC, FG CoA mostly includes findings from lab analyses of a specific batch. For each beta-Caryophyllene, >=80%, FCC, FG CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
beta-Caryophyllene, >=80%, FCC, FG may be tested according to a variety of international standards, such as European Pharmacopoeia (beta-Caryophyllene, >=80%, FCC, FG EP), beta-Caryophyllene, >=80%, FCC, FG JP (Japanese Pharmacopeia) and the US Pharmacopoeia (beta-Caryophyllene, >=80%, FCC, FG USP).
